Researchers have found evidence that could help explain why some anemic CKD patients are resistant to treatment with erythropoiesis stimulating agents. Patients on high-dose ESA had significantly ...

ESA treatment in lower-risk MDS patients is linked to improved overall survival and quality of life. Avoiding red blood cell transfusions is associated with significantly better health-related quality ...

Jula K. Inrig, MD Investigators believe elevated levels of endogenous soluble erythropoietin receptors may have a role. SAN DIEGO—Researchers have found evidence that could help explain why some ...

In a Japanese study, approximately 1 in 8 CKD patients with anemia failed to respond to darbepoetin alfa therapy. Specific factors may predict better initial response to darbepoetin alfa in patients ...

Only about a quarter of patients who have myelodysplastic syndrome (MDS) experienced hematologic improvement with erythropoiesis-stimulating agents (ESAs). Patients with lower-risk myelodysplastic ...

Please provide your email address to receive an email when new articles are posted on . Patients switched to oral vadadustat had hemoglobin levels similar to those on a long-acting ...